Similar articles for PMID: 11850494

Year	Number of Results
1989	4
1991	1
1994	4
1997	3
1998	2
1999	3
2000	6
2001	9
2002	24
2003	32
2004	35
2005	26
2006	31
2007	37
2008	28
2009	27
2010	20
2011	17
2012	14
2013	14
2014	15
2015	8
2016	7
2017	4
2018	6
2019	5
2020	3
2021	8
2022	7
2023	5
2024	0

1

Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.

Wagner HN Jr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, Lamonica DM, Conti PS. Wagner HN Jr, et al. J Nucl Med. 2002 Feb;43(2):267-72. J Nucl Med. 2002. PMID: 11850494 Free article. Review.

2

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA. Wiseman GA, et al. J Nucl Med. 2003 Mar;44(3):465-74. J Nucl Med. 2003. PMID: 12621016 Free article. Clinical Trial.

3

Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.

Marcus R. Marcus R. Semin Oncol. 2005 Feb;32(1 Suppl 1):S36-43. doi: 10.1053/j.seminoncol.2005.01.012. Semin Oncol. 2005. PMID: 15786024

4

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Witzig TE, et al. J Clin Oncol. 2002 May 15;20(10):2453-63. doi: 10.1200/JCO.2002.11.076. J Clin Oncol. 2002. PMID: 12011122 Clinical Trial.

5

Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

Gordon LI. Gordon LI. Semin Oncol. 2003 Dec;30(6 Suppl 17):23-8. doi: 10.1053/j.seminoncol.2003.10.003. Semin Oncol. 2003. PMID: 14710400 Review.

6

Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.

Witzig TE. Witzig TE. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S91-5. doi: 10.1007/s002800100312. Cancer Chemother Pharmacol. 2001. PMID: 11587375 Review.

7

Logistics of therapy with the ibritumomab tiuxetan regimen.

Meredith RF. Meredith RF. Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S35-8. doi: 10.1016/j.ijrobp.2006.06.009. Int J Radiat Oncol Biol Phys. 2006. PMID: 16979437 Review.

8

A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.

Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, Kohl V, Adamson PC, Ayello J, vande Ven C, Perkins SL, Cairo MS; Children's Oncology Group. Cooney-Qualter E, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5652s-5660s. doi: 10.1158/1078-0432.CCR-07-1060. Clin Cancer Res. 2007. PMID: 17875803 Clinical Trial.

9

Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.

Witzig TE. Witzig TE. Drugs Today (Barc). 2004 Feb;40(2):111-9. doi: 10.1358/dot.2004.40.2.799423. Drugs Today (Barc). 2004. PMID: 15045033 Review.

10

The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).

Bischof Delaloye A. Bischof Delaloye A. Leuk Lymphoma. 2003;44 Suppl 4:S29-36. doi: 10.1080/10428140310001616935. Leuk Lymphoma. 2003. PMID: 15154740 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

377 results

Results by year